SLEEP 2026 | Advances in clinical management of sleep apnea: KPAP, GLP-1 agonists, & more

Yeah, I thought that quite a few things, a number of things really, but one that stood out was, you know, KPAP used in the treatment of obstructive sleep apnea. And I think the idea was trying to ensure that, you know, during inspiration as well as in expiration, you know, you have sufficient pressure. So I thought that was good, but it was really revisiting what was initially thought of as a modality for treating obstructive sleep apnea. And then, you know, it was CPAP, APAP, or BiPAP. But now, going back to that technology, and I thought that that was pretty interesting. It was a compelling presentation by the presenter. The other thing was, you know, management of obesity with, you know, the GLP-1 agonists and other, you know, incretin-based nutritional or medicinal pharmacological therapies. I thought that that was interesting. The presentation walked us through challenges, real case scenarios, and what to do with respect to clinical excellence, access, and even managing patient challenges with respect to things like insurance coverage. There were cases where an individual didn’t have any challenge. Another one had a challenge in how to work with those people and walking with them through all of the different side effects that they may face and how to deal with that. I thought that was pretty interesting as well. And there were tons of stuff that was presented that I thought was great. You know, managing sleep disorders in neurological conditions as well, I thought that that was excellent as well, so it was, it was a beautiful, informative and very wonderful session.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.